Testing a new immunotherapy drug combined with chemotherapy for advanced lung lining cancer

Plain-English translation of NCT07885319 on ClinicalTrials.gov ↗ · Source last updated November 2026 · Translation generated November 2026 · How we translate trials

Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.

What is this trial?

This trial is testing whether a medication called ivonescimab, when combined with two standard chemotherapy drugs, can help treat advanced malignant pleural mesothelioma — a serious cancer that develops in the tissue lining the lungs. The study has two phases: first, doctors will test different doses of the medication to make sure it's safe, and then they'll test whether it actually helps patients live longer and feel better. You would receive the medication and chemotherapy together, and then continue with the medication alone for a while afterward.

Mesothelioma is a very difficult cancer to treat, and people diagnosed with it don't have many good treatment options right now. This new treatment combines an immunotherapy approach (which helps your body fight cancer) with chemotherapy to see if it works better than chemotherapy alone.

Do you qualify?

You likely qualify if…

you are between 18 and 75 years old
you have been diagnosed with advanced malignant pleural mesothelioma that cannot be treated with surgery
you have not received any prior chemotherapy or other cancer treatment for your advanced disease
you are in good enough health to tolerate the study treatment (your doctor will confirm this)
you have at least one measurable tumor that can be seen on imaging scans

You likely don't qualify if…

you have an active autoimmune disease that requires treatment
you have uncontrolled high blood pressure or are at high risk for serious bleeding
you currently have interstitial lung disease or inflammation of your lungs
you have an active infection that requires antibiotics or other treatment
you are pregnant, breastfeeding, or have another active cancer requiring treatment

What participation looks like

You would receive the new medication by IV infusion every 3 weeks, along with two chemotherapy drugs, for 4 to 6 cycles. After that, you would continue receiving the new medication alone (or sometimes with one of the chemotherapy drugs) every 3 weeks as maintenance treatment. Throughout the study, your doctors will monitor your health with regular blood tests, imaging scans, and visits to check how you're responding. The trial will also collect small tissue and fluid samples from your lungs to help researchers understand how the treatment works.

AI-generated summary from trial data · Nov 10, 2026 · Not medical advice

Trial locations(3 sites)

China

Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai Municipality

Shanghai Chest Hospital, Shanghai, Shanghai Municipality

West China Hospital of Sichuan University, Chengdu, Sichuan